Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28746
Title: PD-L1 copy number loss in NSCLC associates with reduced PD-L1 tumour staining and a cold immunophenotype.
Austin Authors: Aujla, Savreet;Aloe, Christian;Vannitamby, Amanda;Hendry, Shona;Rangamuwa, Kanishka;Wang, Hao;Vlahos, Ross;Selemidis, Stavros;Leong, Tracy L ;Steinfort, Daniel;Bozinovski, Steven
Affiliation: Respiratory and Sleep Medicine
Department of Respiratory Medicine, Royal Melbourne Hospital, Melbourne, Australia
Department of Anatomical Pathology, St Vincent's Hospital, Melbourne, Victoria, Australia
School of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Faculty of Medicine, University of Melbourne, Parkville, Victoria, Australia
Issue Date: May-2022
Date: 2022-02-04
Publication information: Journal of Thoracic Oncology 2022; 17(5): 675-687
Abstract: PD-L1 copy number gains may be predictive of clinical response to immunotherapy in NSCLC. This study investigated PD-L1 copy number variations in tumour resection and bronchoscopy biopsies and its relationship with PD-L1 tumour cell staining and inflammatory gene expression. PD-L1 gene copy number and mRNA expression were evaluated by real time PCR in surgically resected NSCLC tumour biopsies (n= 87) and control biopsies (n=20). A second cohort (n= 15) of bronchoscopy derived tumour biopsies were analysed, including multiple biopsies from the same patient across different anatomical sites. PD-L1 mRNA levels strongly correlated with PD-L1 tumour staining (r= 0.55, p< 0.0001). Interferonγ (IFNγ) mRNA expression associated with PD-L1 immune cell staining, but not PD-L1 tumour cell staining. In contrast, PD-L1 copy number positively associated PD-L1 tumour staining, but not PD-L1 immune cell staining. PD-L1 copy number analysis detected loss (15/87= 17%) and gain (5/87= 7%) of copy number. Tumours with low PD-L1 copy number expressed significantly reduced levels of inflammatory (INFγ, IL-6, IL-1, MMP-9) and immunosuppressive (IL-10, TGFβ) mediators. Analysis of bronchoscopy derived biopsies demonstrated low heterogeneity in copy number values across different anatomical sites, in contrast to more variable PD-L1 mRNA expression. Low PD-L1 copy number tumours display reduced PD-L1 expression, reduced PD-L1 tumour cell staining and an immunological cold tumour microenvironment. Since PD-L1 copy number values are highly stable across different tumour regions, its evaluation may represent a robust and complimentary biomarker for predicting response to immunotherapy, where low copy number may predict lack of response.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28746
DOI: 10.1016/j.jtho.2022.01.013
ORCID: 0000-0002-1950-1505
Journal: Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
PubMed URL: 35124252
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35124252/
Type: Journal Article
Subjects: NSCLC
PD-L1
biomarkers
copy number
immunotherapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

32
checked on Jun 17, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.